Investorideas.com

Get investor ideas from our AI, cannabis, cleantech, crypto, gaming, mining, sports podcasts - be a guest or sponsor: call 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

Inotiv Makes $545 Million Bid for Envigo RMS Holdings to Fortify Research and Drug Discovery Platforms
September 22, 2021 (Investorideas.com Newswire) Shares of Inotiv Inc. traded 27% higher to a new 52-week high after the company reported it entered into agreement to acquire Envigo RMS Holding Corp. in a cash and stock deal valued at $545 million

Edessa Biotech Shares Rise 87% on Positive Findings in Phase 2 Monoclonal Antibody COVID-19 Study
September 21, 2021 (Investorideas.com Newswire) Edesa Biotech Inc. shares reached a new 52-week high after the company reported positive results from its Phase 2/3 monoclonal antibody study in hospitalized COVID-19 patients.

'Poised for Two Key Readouts in Q1/22' as Biopharma Advances Pipeline
September 21, 2021 (Investorideas.com Newswire) Rezolute's two drug candidates, one for congenital hyperinsulinism and the other for diabetic macular edema, are discussed in an H.C. Wainwright & Co. report.

Target Price Raised On Biopharma After It Acquires Company, Splits Stock
September 21, 2021 (Investorideas.com Newswire) AzurRx BioPharma now has five additional shots on goal "with the imminent full acquisition of just one compound," a ROTH Capital Partners report noted.

Instil Bio Receives FDA Approval to Initiate Expanded Phase 2 Advanced Melanoma Study
September 16, 2021 (Investorideas.com Newswire) Shares of Instil Bio Inc. traded 16% higher after the company reported it received IND clearance from the U.S. FDA to initiate a Phase 2 clinical trial in advanced melanoma patients.

French Biotech Firm Initiates Pivotal Phase 3 Study of Lanifibranor in 900 NASH Patients
September 16, 2021 (Investorideas.com Newswire) ROTH Capital Partners LLC advised in a research report that Inventiva S.A. has initiated enrollment in its highly anticipated pivotal Phase 3 Study of Lanifibranor in individuals diagnosed with nonalcoholic steatohepatitis.

Medical Technology Stock News - Neovasc (NASDAQ: NVCN) Announces FDA Approval of COSIRA-II Clinical Trial
Vancouver, British Columbia and Minneapolis, Minnesota - September 16, 2021 (Newsfile Corp.) (Investorideas.com Newswire) Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received FDA approval for the Investigational Device Exemption ("IDE") regarding the COSIRA-II IDE Clinical Trial.

Biopharma Co. Posts Positive Objective Response & Disease Control Rates in Ovarian Cancer Studies
September 15, 2021 (Investorideas.com Newswire) H.C. Wainwright & Co. advised in a research report that updated data from Mersana Therapeutics Inc.'s expansion study supports its UPLIFT Study and will provide the basis for a new Phase 3 study in 2022. H.C. Wainwright rates Mersana a "Buy" with a target price of $28.00/share.

aTyr Pharma's Fusion Protein Achieves Consistent Dose Response in Pulmonary Sarcoidosis Trial
September 14, 2021 (Investorideas.com Newswire) Shares of aTyr Pharma Inc. traded 48% higher after the firm reported its ATYR1923 produced positive results in a Phase 1b/2a clinical study by demonstrating consistent favorable dose responses in pulmonary sarcoidosis patients.

Sanofi Makes US$1.9 Billion Offer to Buy Kadmon Holdings to Solidify Its Transplant Business
September 9, 2021 (Investorideas.com Newswire) Shares of Kadmon Holdings Inc. traded 70% higher after the firm reported it agreed to be acquired by Sanofi SA for $9.50 per share in cash.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Related Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

Annovis Bio to Present at the Cantor Global Healthcare Conference

Dr. Maria Maccecchini will present a corporate update on Tuesday, September 28 at 11:20am ET

Berwyn, Pennsylvania--(Newsfile Corp. - September 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Founder, President and CEO Maria Maccecchini, Ph.D. will present at the virtual Cantor Global Healthcare Conference to be held on September 27-30, 2021.The presentation will be available during a live webcast on Tuesday, September 28 at 11:20am ET,...

Sona Updates on Strategy and Test Development Progress

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021

Halifax, Nova Scotia--(Newsfile Corp. - September 23, 2021) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona"), a developer of rapid, point-of-care diagnostic tests and owner of proprietary biocompatible gold nanorod ("GNR") technology, is pleased to provide an update on its strategy and on the progress of its concussion and bovine tuberculosis rapid test development programs. Sona leverages on its core GNR manufacturing technology, scientific experience, and laboratory...

PharmaDrug's Super Smart Launches Slim MycoWeRx Brand of Functional Mushrooms
Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division is launching its own premium blend of functional mushrooms. MycoWe℞ Infinite will initially debut for sale in the United States before also being...

Awakn Life Sciences Acquires Exclusive Rights to MDMA Research from Imperial College London

This Was the World's First Published Study Assessing MDMA-Assisted Psychotherapy as a Treatment for Addiction

Toronto, Ontario--(Newsfile Corp. - September 23, 2021) - Awakn Life Sciences Corp., (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn) a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, announced today that it has acquired the exclusive rights to the data from the phase IIa Bristol Imperial MDMA in Alcoholism Study (BIMA) from Imperial College London, which has one of the world's leading psychedelics research centers.BIMA was an Open-label safety, tolerability and proof-of-concept study...

Relay's Cybeats to Sponsor the 8th Annual Cyber Senate Control Systems Cybersecurity USA Conference in Florida
Toronto, Ontario--(Newsfile Corp. - September 22, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company") a developer of technological innovation, including Cybeats holistic platform which includes SBoM Studio and a Microagent, is pleased to announce the sponsorship of the 8th Annual Cyber Senate Control Systems Cybersecurity USA Conference ("Cyber Senate") in Orlando, Florida.8th Annual Control Systems Cybersecurity USA September 22 - 24, 2021 Mystic Dunes Resort Orlando, FloridaChris Blask, Relay's Vice President of Strategy,...

Subscribe to Biotech News